Abstract P5-11-11: A Phase I Safety Study of Topical Calcitriol (BPM31543) for the Prevention of Chemotherapy-Induced Alopecia
February 2017
in “
Cancer Research
”
TLDR Topical calcitriol appears safe and may reduce hair loss during chemotherapy.
The study investigated the safety and efficacy of topical calcitriol (BPM31543) for preventing chemotherapy-induced alopecia (CIA) in a phase I trial involving up to 31 women with breast cancer, gynecologic cancer, and sarcomas. Participants applied BPM31543 to their scalps twice daily before and during taxane-based chemotherapy. Preliminary results from 24 enrolled subjects (13 evaluable) indicated that the treatment was safe and well-tolerated, with mild to moderate adverse events. Efficacy data showed promising results, with a reduction in hair loss at higher doses (≥ 20 μg/mL), where only 43% of patients experienced ≥ 75% hair loss compared to 85% at lower doses (5/10 μg/mL). These findings led to the study's amendment to include higher dose cohorts of 60 and 80 μg/mL.